证券代码：002950 证券简称：奥美医疗 公告编号：2024-002 奥美医疗用品股份有限公司 关于 2023 年度计提信用及资产减值损失的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）根据《企业会计准则》、《深圳证券 交易所股票上市规则》及公司计提减值准备的有关制度，基于谨慎性原则，公司对合并报表 范围内截至2023年12月31日的各类应收款项、合同资产、存货、固定资产、在建工程、无 形资产、开发支出等资产进行了全面清查，对各项资产减值的可能性进行了充分的评估和分 析，对存在减值迹象的资产计提相应减值准备。 一、计提信用及资产减值损失概述 公司2023年度信用及资产减值损失合计计提10,256万元人民币，其中应收账款计提减 值准备767万元人民币，其他应收款计提减值准备68万元人民币，存货跌价准备计提9,421 万元人民币。 剔除外币报表折算差异影响，本次发生的信用及资产减值损失预计将减少2023年度当 期损益（税前）共计10,256万元人民币。 二、信用及资产减值损失计提情况 （一）应收账款及其他应收款 ...

第一章 总则 奥美医疗用品股份有限公司 独立董事工作制度 奥美医疗用品股份有限公司 独立董事工作制度 （2023 年 12 月修订稿） 奥美医疗用品股份有限公司 独立董事工作制度 第一条 为进一步完善奥美医疗用品股份有限公司（以下简称 "公司"）的法人治理结构，强化对董事会及管理层的约束和监督机 制，更好地维护中小股东利益，促进公司的规范运作，根据《中华 人民共和国公司法》《上市公司独立董事管理办法》《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》《深圳 证券交易所股票上市规则》及《奥美医疗用品股份有限公司章程》 （以下简称"《公司章程》"）等相关规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与 公司及其主要股东、实际控制人不存在直接或间接利害关系，或者 其他可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控 制人等单位或者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当 按照法律、行政法规、《公司章程》和本制度的要求，认真履行职责， 在董事会中发挥参与决策、监督制衡、专业咨询作用，维护上市 ...

二、董事会会议审议情况 证券代码：002950 证券简称：奥美医疗 公告编号：2023-028 奥美医疗用品股份有限公司 第三届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 奥美医疗用品股份有限公司（以下简称"公司"）第三届董事会第六次会议于 2023 年 12 月 28 日（星期四）以通讯的方式召开。会议通知已于 2023 年 12 月 25 日通过邮件的方式送达各位董事。本次会议应出席董事 7 人，实际出席董事 7 人。 会议由董事长崔金海主持，监事、高管列席。会议召开符合有关法律、法规、 规章和《公司章程》的规定。经各位董事认真审议，会议形成了如下决议： 特此公告。 （一）审议通过《关于审议公司独立董事工作制度的议案》 表决结果：7 票同意，0 票反对，0 票弃权。 具体内容详见公司披露于《证券时报》《中国证券报》《上海证券报》《证券 日报》与巨潮资讯网（http://www.cninfo.com.cn）的《奥美医疗用品股份有限 公司独立董事工作制度》。 （二）审议通过《关于调整第三届董事会审计委员会委 ...

为保障公司审计委员会的正常运行，根据《中华人民共和国公司法》《上市 公司独立董事管理办法》《公司章程》等相关规定，结合公司实际情况，公司董 事会同意选举独立董事蔡天智先生为公司第三届董事会审计委员会委员，任期自 第三届董事会第六次会议审议通过之日起至第三届董事会任期届满之日止。 奥美医疗用品股份有限公司 关于调整公司第三届董事会审计委员会成员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）于 2023 年 12 月 28 日召 开第三届董事会第六次会议，审议通过了《关于调整第三届董事会审计委员会委 员的议案》，同意对公司第三届董事会审计委员会部分成员进行调整。 根据中国证券监督管理委员会颁布的《上市公司独立董事管理办法》有关规 定，审计委员会成员应当为不在上市公司担任高级管理人员的董事。为进一步完 善公司治理结构，充分发挥董事会专门委员会在公司治理中的作用，公司董事会 对第三届董事会审计委员会部分成员进行调整，公司董事长、总裁崔金海先生不 再担任第三届董事会审计委员会委员职务。 证券代码：002950 证券简 ...

证券代码：002950 证券简称：奥美医疗 公告编号：2023-027 股东陈浩华先生保证向公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 奥美医疗用品股份有限公司（以下简称"公司"）于 2023 年 4 月 29 日在公司指定披露 信息的媒体《证券时报》、《上海证券报》、《中国证券报》、《证券日报》以及巨潮资讯网 （www.cninfo.com.cn）披露了《关于持股 5%以上的股东股份减持计划提前终止暨后续减持 计划的预披露公告》（公告编号：2023-014）及 2023 年 8 月 11 日披露了《关于持股 5%以 上股东减持比例超过 1%的公告》（公告编号：2023-018）、《关于持股 5%以上股东减持计划 时间过半的进展公告》（公告编号：2023-019），对公司股东陈浩华先生的股份减持计划预披 露、减持比例超过 1%及股份减持计划时间过半进展进行了披露。 近日，公司收到了陈浩华先生发来的《关于减持股份进展情况暨减持计划期限届满的告 知函》，其股份减持计划期限届满。现将陈浩华先生股份减持情况公告如下： ...

关于奥美医疗用品股份有限公司 北京德恒（南京）律师事务所 2023年第一次临时股东大会的法律意见 北京德恒（南京）律师事务所 关于 奥美医疗用品股份有限公司 2023 年第一次临时股东大会的法律意见 德恒18G20220067-00003号 致：奥美医疗用品股份有限公司 北京德恒（南京）律师事务所接受奥美医疗用品股份有限公司（以下简称"公 司"）委托，指派蔡丹律师、赵米悦律师（以下简称"本所律师"）出席公司 2023 年第一次临时股东大会（以下简称"本次股东大会"），对本次股东大会的合法性 进行见证并出具法律意见。 本法律意见根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）等现行有效的法律、法规、规范性文件以及 《奥美医疗用品股份有限公司章程（以下简称"《公司章程》"）的规定而出具。 为出具本法律意见，本所律师审查了公司本次股东大会的有关文件和材料， 同时本所律师出席本次股东大会会议，依法参与了现场参会人员身份证明文件的 核验工作，见证了本次股东大会召开、表决和形成决议的全过程。 在本法律意 ...

证券代码：002950 证券简称：奥美医疗 公告编号：2023-026 奥美医疗用品股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 一、会议召开和出席情况 1、 召开时间：2023 年 11 月 23 日（星期四）14:30 6、 本次会议的召集、召开符合《中华人民共和国公司法》、《上市公司股 东大会规则》、《深圳证券交易所股票上市规则》等有关法律、行政法规、部门 规章、规范性文件和《奥美医疗用品股份有限公司章程》的有关规定。 二、会议出席情况 （一）股东出席的总体情况 参加本次股东大会现场会议和网络投票表决的股东及股东代理人共 11 人， 代表有表决权的公司股份数合计为 414,593,301 股，占公司有表决权股份总数 633,265,407 股的 65.4691%。其中：通过现场投票的股东共 5 人，代表有表决 权的公司股份数合计为 239,091,391 股，占公司有表决权股份总数 633,265,407 股的 37.7553%；通过网络投票的股东共 6 人，代表有表决权的公司股份数合计 ...

Financial Performance - The company's revenue for Q3 2023 was ¥591,568,208.13, a decrease of 36.58% compared to the same period last year[5] - The net profit attributable to shareholders was -¥6,634,324.87, representing a decline of 92.88% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥42,631,405.57, down 18.55% from the previous year[5] - Total operating revenue for Q3 2023 was CNY 2,018,286,601.72, a decrease of 34.3% compared to CNY 3,067,161,380.95 in the same period last year[18] - Net profit for Q3 2023 was CNY 145,096,053.88, a decline of 26.3% compared to CNY 196,749,394.55 in Q3 2022[19] - The total comprehensive income for the third quarter was CNY 142,881,909.17, a decrease from CNY 289,534,919.49 in the previous period[20] Earnings and Shareholder Information - The company's basic and diluted earnings per share were both -¥0.0105, a decrease of 92.87% year-on-year[5] - Basic and diluted earnings per share for the quarter were CNY 0.2375, down from CNY 0.3109 year-over-year[20] - The total number of ordinary shareholders at the end of the reporting period was 45,447[11] - The top shareholder, Cui Jinhai, holds 23.02% of the shares, totaling 145,794,859 shares[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,176,168,600.57, a decrease of 9.94% from the end of the previous year[5] - The company's total assets as of September 30, 2023, amounted to CNY 5,176,168,600.57, a decrease from CNY 5,747,507,000.10 at the beginning of the year[16] - Current assets totaled CNY 1,828,283,232.00, down from CNY 2,398,959,626.70 at the start of the year, reflecting a decline of 23.8%[15] - The total liabilities decreased to CNY 1,940,298,066.35 from CNY 2,616,522,450.63, indicating a reduction of 26.0%[16] - The company reported a total equity attributable to shareholders of ¥3,211,265,730.42, an increase of 3.55% from the previous year[5] Cash Flow - The operating cash flow net amount for the year-to-date was ¥459,259,090.89, a decrease of 49.02%[5] - Net cash flow from operating activities was CNY 459,259,090.89, significantly lower than CNY 900,860,648.94 in the same period last year[22] - Cash inflow from operating activities totaled CNY 2,379,250,640.27, compared to CNY 3,691,129,338.86 in the previous year[21] - Cash outflow from operating activities was CNY 1,919,991,549.38, down from CNY 2,790,268,689.92 year-over-year[21] - Net cash flow from investing activities was negative CNY 147,989,850.38, an improvement from negative CNY 1,067,174,157.15 in the previous year[22] - Cash flow from financing activities resulted in a net outflow of CNY 422,568,982.11, compared to a net outflow of CNY 236,928,160.88 in the same period last year[22] - The ending balance of cash and cash equivalents was CNY 393,655,682.98, an increase from CNY 280,149,583.65 year-over-year[22] - The company's cash and cash equivalents increased to CNY 522,204,672.55 from CNY 393,948,041.15, representing a growth of 32.6%[14] Operational Costs and R&D - Total operating costs for Q3 2023 were CNY 1,807,626,230.75, down 32.4% from CNY 2,675,982,938.94 year-on-year[18] - The company reported R&D expenses of CNY 60,060,955.75 for Q3 2023, an increase of 31.5% compared to CNY 45,635,755.64 in the previous year[19] Inventory and Borrowings - Inventory as of September 30, 2023, was CNY 831,236,165.09, a decrease of 5.3% from CNY 877,326,555.66 at the beginning of the year[14] - Short-term borrowings decreased significantly to CNY 443,350,309.73 from CNY 792,092,140.47, a reduction of 44.1%[16] Audit Status - The company has not undergone an audit for the third quarter report[23]

关于召开 2023 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）定于2023年11月23日（星期 四）14:30召开2023年第一次临时股东大会，本次会议采取现场表决与网络投票 相结合的方式召开，现将有关事项通知如下： 证券代码：002950 证券简称：奥美医疗 公告编号：2023-025 奥美医疗用品股份有限公司 一、 召开会议的基本情况 1、会议届次：2023 年第一次临时股东大会 2、会议召集人：董事会。第三届董事会第五次会议审议通过了关于召开本 次股东大会的议案。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的有关规定。 4、会议召开的日期、时间： （1）现场会议：2023 年 11 月 23 日（星期四）14:30 （2）网络投票： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2023 年 11 月 23 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥1.43 billion, a decrease of 33.16% compared to ¥2.13 billion in the same period last year[30]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥157 million, down 45.87% from ¥290 million in the same period last year[30]. - The net cash flow from operating activities was approximately ¥207 million, a decline of 62.99% compared to ¥559 million in the same period last year[30]. - The basic earnings per share for the first half of 2023 was ¥0.248, a decrease of 45.86% from ¥0.458 in the same period last year[30]. - The total assets at the end of the reporting period were approximately ¥5.29 billion, down 7.89% from ¥5.75 billion at the end of the previous year[30]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥3.22 billion, an increase of 3.77% from ¥3.10 billion at the end of the previous year[30]. - The company reported a net profit for the first half of 2023 of CNY 154,909,401.98, a decrease of 46.5% compared to CNY 290,008,635.61 in the same period of 2022[178]. - The total comprehensive income for the first half of 2023 was CNY 152,711,366.72, compared to CNY 330,806,041.98 in the same period of 2022[178]. Market and Industry Trends - The global wound management market is expected to grow from $13 billion in 2017 to $17.8 billion by 2024, with a compound annual growth rate of 4.6%[40]. - The global bandage and medical dressing market was valued at $18.84 billion in 2015 and is projected to reach $31.3 billion by 2025[40]. - The demand for wound care is increasing due to the aging population and the rise in chronic wounds, leading to a stable growth in the medical dressing industry[40]. - The global market for medical dressings and bandages is projected to grow significantly, with a focus on high-end medical dressing products, particularly in developed economies like the EU and the US[41]. - The domestic medical dressing market in China is experiencing rapid expansion, maintaining a double-digit growth rate due to improved healthcare resources and rising living standards[43]. - China has become the largest exporter of medical dressings globally, with leading companies achieving world-class quality in traditional wound care products[43]. Product Development and Innovation - The company is focusing on the development of advanced dressing products that promote wound healing in a moist environment[39]. - The company is expanding its product line to include infection protection products and advanced dressing series, aiming to provide a comprehensive product supply service[48]. - The company’s medical dressings are designed with advanced features such as high absorption capacity and non-adhesive properties to promote healing[50]. - The company utilizes advanced materials like polyurethane films for surgical drapes, ensuring a sterile environment and preventing contamination[51]. - The company introduced advanced dressing products with unique features, including a hemostatic dressing that accelerates coagulation and absorbs liquid quickly, reducing blood loss[52]. - The hydrophilic fiber dressing can absorb liquid up to 30 times its weight, providing multifunctional benefits such as promoting healing and inhibiting bacteria[52]. - The company achieved a notable improvement in the performance of its disinfectant wipes, with a bactericidal rate of up to 99.99% against common pathogens[55]. - The company has introduced innovative products like the medical cooling patch, which provides sustained cooling for 6-8 hours[58]. Financial Management and Risks - The company faces exchange rate fluctuation risks, as a large portion of sales revenue is in foreign currencies, which can affect product pricing and operating income[8]. - The company reported a loss of 5,946.24 million CNY from derivative investments during the reporting period[86]. - The company utilized financial derivatives to hedge against exchange rate risks, effectively mitigating the impact of currency fluctuations on asset and liability values[86]. - The company has a significant market presence, exporting to nearly 40 countries and regions, with a continuous 15-year leadership in China's medical dressing export industry[65]. - The company has a competitive advantage in advanced manufacturing, quality control, and technological innovation, built over more than 20 years of development[59]. Corporate Governance and Social Responsibility - The company has actively engaged in social responsibility initiatives, including poverty alleviation and employee care programs[106]. - In 2023, the company formed five teams to visit and support employees in need, demonstrating its commitment to employee welfare[106]. - The company was recognized as a training point for employee representatives by the provincial labor union, highlighting its commitment to democratic management[107]. - The company launched a campaign to honor model workers, promoting a culture of excellence and innovation among employees[108]. Future Outlook and Strategic Plans - The future outlook includes plans for market expansion and the development of new technologies in medical supplies[53]. - The company aims to enhance its competitive edge through strategic acquisitions and partnerships in the healthcare sector[53]. - The company has established a complete industrial chain for medical dressings, infection protection products, and medical non-woven products, achieving integrated, large-scale, and intelligent production[60].